Literature DB >> 33245463

BKCa Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats.

Ana Paula Ferraz1, Fernando A C Seara1,2, Emanuelle F Baptista1, Thais S Barenco1, Thais B B Sottani1, Natalia S C Souza1, Ainá E Domingos1, Raiana A Q Barbosa1, Christina M Takiya1, Marcos T Couto3, Gabriel O Resende3, Antonio C Campos de Carvalho1, Cristiano G Ponte3, Jose Hamilton M Nascimento4.   

Abstract

PURPOSE: In the present study, the therapeutic efficacy of a selective BKCa channel opener (compound X) in the treatment of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) was investigated.
METHODS: PAH was induced in male Wistar rats by a single injection of MCT. After two weeks, the MCT-treated group was divided into two groups that were either treated with compound X or vehicle. Compound X was administered daily at 28 mg/kg. Electrocardiographic, echocardiographic, and haemodynamic analyses were performed; ex vivo evaluations of pulmonary artery reactivity, right ventricle (RV) and lung histology as well as expression levels of α and β myosin heavy chain, brain natriuretic peptide, and cytokines (TNFα and IL10) in heart tissue were performed.
RESULTS: Pulmonary artery rings of the PAH group showed a lower vasodilatation response to acetylcholine, suggesting endothelial dysfunction. Compound X promoted strong vasodilation in pulmonary artery rings of both control and MCT-induced PAH rats. The untreated hypertensive rats presented remodelling of pulmonary arterioles associated with increased resistance to pulmonary flow; increased systolic pressure, hypertrophy and fibrosis of the RV; prolongation of the QT and Tpeak-Tend intervals (evaluated during electrocardiogram); increased lung and liver weights; and autonomic imbalance with predominance of sympathetic activity. On the other hand, treatment with compound X reduced pulmonary vascular remodelling, pulmonary flow resistance and RV hypertrophy and afterload.
CONCLUSION: The use of a selective and potent opener to activate the BKCa channels promoted improvement of haemodynamic parameters and consequent prevention of RV maladaptive remodelling in rats with MCT-induced PAH.

Entities:  

Keywords:  BKCa channel opener; Monocrotaline; Pulmonary arterial hypertension; Right ventricular dysfunction

Mesh:

Substances:

Year:  2020        PMID: 33245463     DOI: 10.1007/s10557-020-07115-5

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  46 in total

1.  Voltage and Ca2+ activation of single large-conductance Ca2+-activated K+ channels described by a two-tiered allosteric gating mechanism.

Authors:  B S Rothberg; K L Magleby
Journal:  J Gen Physiol       Date:  2000-07-01       Impact factor: 4.086

2.  Function of BKCa channels is reduced in human vascular smooth muscle cells from Han Chinese patients with hypertension.

Authors:  Yan Yang; Peng-Yun Li; Jun Cheng; Liang Mao; Jing Wen; Xiao-Qiu Tan; Zhi-Fei Liu; Xiao-Rong Zeng
Journal:  Hypertension       Date:  2012-12-10       Impact factor: 10.190

3.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

4.  [Updated clinical classification of pulmonary hypertension].

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  Turk Kardiyol Dern Ars       Date:  2014-10

5.  Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension.

Authors:  P Petitpretz; F Brenot; R Azarian; F Parent; B Rain; P Herve; G Simonneau
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

6.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

7.  Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.

Authors:  Sébastien Bonnet; Eric Dumas-de-La-Roque; Hugues Bégueret; Roger Marthan; Michael Fayon; Pierre Dos Santos; Jean-Pierre Savineau; Etienne-Emile Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

8.  Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia.

Authors:  S L Archer; J M Huang; H L Reeve; V Hampl; S Tolarová; E Michelakis; E K Weir
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

Review 9.  Potassium channels in pulmonary arterial hypertension.

Authors:  Olivier Boucherat; Sophie Chabot; Fabrice Antigny; Frédéric Perros; Steeve Provencher; Sébastien Bonnet
Journal:  Eur Respir J       Date:  2015-09-04       Impact factor: 16.671

Review 10.  Mechanisms of disease: pulmonary arterial hypertension.

Authors:  Ralph T Schermuly; Hossein A Ghofrani; Martin R Wilkins; Friedrich Grimminger
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419

View more
  5 in total

Review 1.  Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension.

Authors:  Joana Santos-Gomes; Hélène Le Ribeuz; Carmen Brás-Silva; Fabrice Antigny; Rui Adão
Journal:  Biomolecules       Date:  2022-03-22

2.  Piper tectoniifolium Kunth: A New Natural Source of the Bioactive Neolignan (-)-Grandisin.

Authors:  André M Marques; Alexandre Siqueira da Rocha Queiroz; Elsie F Guimarães; Ana Carolina Mafud; Paulo de Sousa Carvalho; Yvonne Primerano Mascarenhas; Thais da Silva Barenco; Pâmella Dourila N Souza; David William Provance; José Hamilton M do Nascimento; Cristiano G Ponte; Maria Auxiliadora C Kaplan; Davyson de Lima Moreira; Maria Raquel Figueiredo
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

Review 3.  Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation.

Authors:  Divya Guntur; Horst Olschewski; Péter Enyedi; Réka Csáki; Andrea Olschewski; Chandran Nagaraj
Journal:  Biomolecules       Date:  2021-11-03

Review 4.  Mechanosensitivity in Pulmonary Circulation: Pathophysiological Relevance of Stretch-Activated Channels in Pulmonary Hypertension.

Authors:  Solène Barbeau; Guillaume Gilbert; Guillaume Cardouat; Isabelle Baudrimont; Véronique Freund-Michel; Christelle Guibert; Roger Marthan; Pierre Vacher; Jean-François Quignard; Thomas Ducret
Journal:  Biomolecules       Date:  2021-09-21

Review 5.  Ion channels as convergence points in the pathology of pulmonary arterial hypertension.

Authors:  Thibault R H Jouen-Tachoire; Stephen J Tucker; Paolo Tammaro
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.